WASHINGTON BIOTECHNOLOGY, INC.

Now in our 24th Year of Service in Drug Development

In Vivo Cancer (Xenograft) Studies

Efficacy Tests for Potential Anti-Cancer Agents (compounds, proteins, vaccines)

-          Our experienced personnel provide quality results and skilled observations

-          Cost-efficient studies with rapid scheduling

-          Data transmitted promptly to Sponsor during dosing/measurement phases

-          Your Project is described in detail – Custom Protocol, Final Report including statistical/graphical analysis of data

-          All of our in vivo studies and cell cultures are carried out at our facility in Columbia, Maryland, U.S.A.

-          All animal species are acquired from established U.S. laboratory animal suppliers (Jackson Laboratories, HSD, CRL or Taconic)

      -   You are invited to use our Protocols or we will customize to fit your Protocol.

  Multiple Cell Lines (Human)  are available for each cancer model :

ORGAN	DISEASE / CELL LINES
Breast	Adenocarcinoma
	MDA-MB-231, MCF-7, BT474, MX-1, HN104, VT203
Colon	Adenocarcinoma
	HT-29, COLO-205, HCC 2998
Liver	Adenocarcinoma
	MHCC97H, Huh-7
Peripheral blood	Leukemia
	HL-60, K562, Dal-3b-M2
Lung	Carcinoma
	H-460, H-358, A549
Skin	Melanoma
	A-375, B16-F10 (mouse/syngeneic)
Pancreas	Adenocarcinoma
	AsPC-1, PANC-1, HPAF-II, BxPC-3, Miapaca-2, MCF-SNCG, U266
Prostate	Adenocarcinoma
	PC-3
Ovarian	Adenocarcinoma
	SK-OV-3, OVCAR-5
Thyroid	Carcinoma
	TT
Brain	Glioma
	U87 MG, C6 (rat)
Peripheral blood	Myeloma
	RPMI-8226

Subcutaneous Xenograft Models:    Using one of our cell lines or client supplied cell line in athymic nude or immunodeficient mice.

Metastasis Models:                          Syngeneic model B16-F10 (mouse)

                          Breast cancer: MDA-MB-231

Orthotopic Models:                          Breast cancer MDA-MB-231

                                                        Liver cancer:  MHCC97H